Announcement • May 14
Cardiff Lexington Corporation to Report Q1, 2026 Results on May 19, 2026 Cardiff Lexington Corporation announced that they will report Q1, 2026 results on May 19, 2026 Announcement • May 01
Cardiff Lexington Corporation has withdrawn its IPO in the amount of $5.999999 million. Cardiff Lexington Corporation has withdrawn its IPO in the amount of $5.999999 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 1,739,130
Price\Range: $3.45
Discount Per Security: $0.276
Transaction Features: Sponsor Backed Offering Announcement • Mar 12
Cardiff Lexington Corporation to Report Q4, 2025 Results on Mar 16, 2026 Cardiff Lexington Corporation announced that they will report Q4, 2025 results at 12:30 PM, US Eastern Standard Time on Mar 16, 2026 Announcement • Jan 06
Cardiff Lexington Corporation Announces Board Changes, Effective December 31, 2025 On December 31, 2025, Daniel Thompson resigned from the Board of Directors of Cardiff Lexington Corporation (the “ Company”), including from his position as Chairman of the Board. Such resignation was not due to any disagreement with the Company on any matter relating to its operations, policies (including accounting or financial policies) or practices. Alex Cunningham, the Company’s Chief Executive Officer and member of the Board of Directors, was appointed as the new Chairman of the Board. Announcement • Dec 16
Cardiff Lexington Corporation has filed an IPO in the amount of $6 million. Cardiff Lexington Corporation has filed an IPO in the amount of $6 million.
Security Name: Common Stock
Security Type: Common Stock Announcement • Nov 07
Cardiff Lexington Corporation to Report Q3, 2025 Results on Nov 14, 2025 Cardiff Lexington Corporation announced that they will report Q3, 2025 results Pre-Market on Nov 14, 2025 Announcement • Aug 15
Cardiff Lexington Corporation announced delayed 10-Q filing On 08/14/2025, Cardiff Lexington Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Announcement • Jul 29
Cardiff Lexington Corporation to Report Q2, 2025 Results on Aug 12, 2025 Cardiff Lexington Corporation announced that they will report Q2, 2025 results on Aug 12, 2025 Announcement • May 03
Cardiff Lexington Corporation has withdrawn its IPO in the amount of $9.6 million. Cardiff Lexington Corporation has withdrawn its IPO in the amount of $9.6 million.
Security Name: Common Shares
Security Type: Common Stock
Securities Offered: 1,600,000
Price\Range: $4 to $6
Discount Per Security: $0.45 Announcement • Jun 13
Cardiff Lexington Corporation Announces Executive Changes On June 5, 2024, Cardiff Lexington Corporation announced termination Zia Choe from her position as Chief Accounting Officer of the Company in connection with a restructuring of the Company’s accounting department. The Company’s Chief Financial Officer, Matthew T. Shafer, will serve as the Company’s principal accounting officer and the Company has hired a new Controller and Staff Accountant to support Mr. Shafer. Announcement • Jan 17
Cardiff Lexington Appoints Kevin Fitzgerald as Managing Director of Nova Ortho and Spine Cardiff Lexington Corporation announced the appointment of Dr. Kevin Fitzgerald, M.D. as Managing Director of Nova Ortho and Spine, the Company's healthcare subsidiary. Dr. Fitzgerald has previously been with Nova Ortho and Spine as a highly qualified member of the management and care team. In his new role as managing director, he will now oversee all aspects of day to day operations, expansion, patient care, provider production, marketing, and company relations as the business continues to grow. Dr. Fitzgerald has over 20 years of experience in the medical profession in various roles including physician, respiratory therapist, and physician's assistant. From 2018 to 2021, Dr. Fitzgerald was the alternate Chief Medical Officer and the in-patient medical director for the Cleveland Clinic throughout Martin County, Florida. He also served as the Chairman of Medicine, Professional Development Physician Champion, Operations Development, Financial Committee Member, Board of Trustees (voting member), and an Instructor for Career Development and Patient Advocacy. In these roles, Dr. Fitzgerald was solely responsible for three hospitals with a total patient capacity of over 550, as well as the supervision of 30 physicians and 12 advanced care providers. Additionally, during his tenure, Dr. Fitzgerald developed several programs to include a physician advisory platform that allowed the hospital system to work closely with private and government insurance. This created a symbiotic relationship while improving care and increasing revenue. Dr. Fitzgerald also continues to serve as a Colonel and the Chief of Aerospace Medicine in the Air National Guard overseeing the state of Florida's entire health program of Aerospace and General Medicine. Dr. Fitzgerald is board certified by the American Academy for Procedural Medicine (AAOPM) for procedural medicine, certified traumatic brain injury specialist, and a life care planner for catastrophic injuries. He earned his Doctor of Medicine from the International University of Health and Sciences and completed his residency at Oakland University in Detroit, MI, a part of the Beaumont Health network, now one of the largest healthcare systems in Michigan. In addition to his medical degree, Dr. Fitzgerald has also earned a Bachelor of Science in physician assistant studies and a Master of Health Science from Nova Southeastern University, as well as a Bachelor of Science in Mass Communications from Towson University. Announcement • Jan 05
Cardiff Lexington Corporation Appoints Zia Choe as Chief Accounting Officer Cardiff Lexington Corporation announced the appointment of Zia Choe as Chief Accounting Officer. Ms. Choe previously served as interim Chief Financial Officer at Cardiff Lexington. In her new role, Ms. Choe will work across all constituencies to help ensure accurate and timely financial reporting, develop policies and procedures which align to enterprise-wide business strategies and accounting professional standards, perform technical accounting diligence on prospective acquisitions, and support on the execution of the Company's strategic growth initiatives to expand on a national scale. Ms. Choe is a highly accomplished finance professional with 17 years of accounting and operational experience. Most recently, Ms. Choe served as a Partner at STK Financial where she was responsible for the financial audit and review of domestic and international clients, provided high level outsourced accounting advisory services, performed financial due diligence for mergers and acquisitions, and assisted in the preparation of 10K and 10Q financial statements and footnotes. Prior to this role, Ms. Choe served as Audit and Assurance Manager at JNK Accountancy Group, where she successfully conducted financial audits in accordance with US GAAP and IFRS measures for various domestic and international clients. She also advised clients on various topics including accounting policies, internal control, risk assessments, fraud, and new accounting standards. Ms. Choe is a certified public accountant. She received her Bachelor of Science degree in hospitality management from Florida International University and her Master of Science equivalent in accounting from the AICPA Accounting Program at Ajou University in Suwon, South Korea. Announcement • May 25
Cardiff Lexington Corp. announced delayed 10-Q filing On 05/24/2023, Cardiff Lexington Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Announcement • Aug 25
Cardiff Lexington Corporation announced delayed amended 10-Q filing On 08/24/2021, Cardiff Lexington Corporation announced that they will be unable to file their amended 10-Q by the deadline required by the SEC. Announcement • Aug 17
Cardiff Lexington Corporation announced delayed 10-Q filing On 08/16/2021, Cardiff Lexington Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Announcement • Jun 05
Cardiff Lexington Corporation (OTCPK:CDIX) acquired Nova Ortho and Spine, LLC for $9.3 million. Cardiff Lexington Corporation (OTCPK:CDIX) acquired Nova Ortho and Spine, LLC for $9.3 million on June 4, 2021. Under the terms, Cardiff paid $2.5 million in cash, 0.9 million J Preferred Stock and a performance based contingent supplement payment of 0.8 million shares. Leonite Capital and an affiliated institutional investor provided a capital investment into Cardiff Lexington Series N Preferred Stock of $3.5 million which facilitated Cardiff Lexington's cash payment portion of the acquisition to the Sellers. No operational changes are planned, and current ownership will remain in place under a ten (10) year Management Agreement. The subsidiary will serve as an acquisition platform to integrate complementary healthcare service providers in neighboring markets and ancillary service providers (chiropractic, physical therapy, imaging, etc.) as we meet rapidly expanding opportunities.
Cardiff Lexington Corporation (OTCPK:CDIX) acquired Nova Ortho and Spine, LLC for $9.3 million. 